Cyclacel Pharmaceuticals Inc (CYCCP) News

Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting

 - Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action...

Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer

- Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of...

Form D - Notice of Exempt Offering of Securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

- New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Strategy...

Form EFFECT - Notice of Effectiveness

Form 424B3 - Prospectus [Rule 424(b)(3)]

Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results

BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form S-1 - General form for registration of securities under the Securities Act of 1933

Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules

BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC...

$8 Million Private Placement Announcement Sends Biotech Flying

Usually when a publicly traded company announces some sort of equity offering, it can be viewed as a dilutive event, thus having a negative effect...